1. Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials
- Author
-
Soledad Fernandez, Xueliang Pan, and Lai Wei
- Subjects
Oncology ,medicine.medical_specialty ,3 + 3 ,Computer science ,Principal (computer security) ,Review ,01 natural sciences ,Phase (combat) ,Institutional support ,3. Good health ,010104 statistics & probability ,03 medical and health sciences ,Dose finding ,0302 clinical medicine ,adaptive designs ,030220 oncology & carcinogenesis ,Internal medicine ,algorithm-based ,oncology Phase I dose-finding design ,medicine ,model-based ,model-assisted ,0101 mathematics ,Statistician - Abstract
The traditional 3 + 3 design continues to be commonly used for Phase I dose-finding oncology trials, despite increasing criticisms and development of innovative methods. Unfortunately, it is a challenge to convince principal investigators to use novel designs. The goal of this paper is to persuade researchers to break away from 3 + 3 design and provide potential solutions to better designs and implementation strategy. We reviewed the statistical methods for adaptive Phase I designs. The barriers among all the major components of the implementation team have been emphasized and potential solutions have been discussed. Institutional support to the principal investigators and statistician, as well as to other team members is essential to design and implement adaptive trials in academic medical institutions.
- Published
- 2019
- Full Text
- View/download PDF